Home / Going-concern warnings / ADIAL PHARMACEUTICALS, INC.
Filed 2026-05-08 路 Form 10-Q 路 Accession 0001213900-26-053907 nano
Price before filing: $1.42 (2026-05-07 close, split/dividend-adjusted)
Market cap at flag: $2.0M (2026-05-08) 路 Latest: $16.1M (2026-10-16)
| Window | ADIL | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +55.6% | +1.0% | +54.6% | 2026-06-08 |
| 90 days | +238.0% | +5.3% | +232.7% | 2026-08-06 |
| 180 days | pending | pending | until 2026-11-04 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"These factors raise substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2026-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.